HK1203978A1 - Polypeptides and antibodies for treating hbv infection and related diseases hbv - Google Patents

Polypeptides and antibodies for treating hbv infection and related diseases hbv

Info

Publication number
HK1203978A1
HK1203978A1 HK15104502.6A HK15104502A HK1203978A1 HK 1203978 A1 HK1203978 A1 HK 1203978A1 HK 15104502 A HK15104502 A HK 15104502A HK 1203978 A1 HK1203978 A1 HK 1203978A1
Authority
HK
Hong Kong
Prior art keywords
hbv
polypeptides
antibodies
related diseases
treating
Prior art date
Application number
HK15104502.6A
Other languages
English (en)
Chinese (zh)
Inventor
Quan Yuan
Tianying Zhang
Wenxin Luo
Yixin Chen
Jun Zhang
Ningshao Xia
Original Assignee
Univ Xiamen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Xiamen filed Critical Univ Xiamen
Publication of HK1203978A1 publication Critical patent/HK1203978A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
HK15104502.6A 2012-06-11 2015-05-12 Polypeptides and antibodies for treating hbv infection and related diseases hbv HK1203978A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210190329 2012-06-11
PCT/CN2013/076832 WO2013185558A1 (zh) 2012-06-11 2013-06-06 用于治疗hbv感染及相关疾病的多肽及抗体

Publications (1)

Publication Number Publication Date
HK1203978A1 true HK1203978A1 (en) 2015-11-06

Family

ID=49757513

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104502.6A HK1203978A1 (en) 2012-06-11 2015-05-12 Polypeptides and antibodies for treating hbv infection and related diseases hbv

Country Status (12)

Country Link
US (2) US9751914B2 (pt)
EP (2) EP2860188B1 (pt)
JP (1) JP6440259B2 (pt)
KR (2) KR102106782B1 (pt)
CN (2) CN103483421B (pt)
AU (1) AU2013276015B2 (pt)
BR (2) BR112014030797A2 (pt)
CA (2) CA2876020C (pt)
ES (2) ES2843675T3 (pt)
HK (1) HK1203978A1 (pt)
IN (1) IN2014DN10288A (pt)
WO (1) WO2013185558A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体
EP3225628A4 (en) * 2014-11-28 2018-03-14 Celltrion Inc. Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus
BR112018007121A2 (pt) 2015-10-09 2018-11-06 Xiamen University anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv
EP3519443A4 (en) 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP6955020B2 (ja) 2017-02-17 2021-10-27 シャアメン ユニバーシティ 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
CN108690134B (zh) * 2017-04-07 2021-07-30 厦门大学 用于治疗乙肝感染及相关疾病的抗体
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
US11932681B2 (en) * 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
AU2020280539A1 (en) * 2019-05-23 2022-01-27 Xiamen University Novel anti-hepatitis B virus antibody and uses thereof
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN111187349A (zh) * 2019-10-30 2020-05-22 四川迈克生物新材料技术有限公司 单克隆抗体的制备方法
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
CN111879932B (zh) * 2020-06-24 2022-09-27 南方医科大学南方医院 乙型肝炎病毒(hbv)特异性b细胞表位检测方法及其应用
CN113234143B (zh) * 2021-05-10 2021-12-14 合肥金域医学检验实验室有限公司 一种快速检测病毒的核酸抗体试剂盒
CN114671947B (zh) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 乙肝病毒不同亚型表面s蛋白高亲和力纳米抗体及其应用
CN116162153A (zh) * 2022-09-01 2023-05-26 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) * 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
CA2251904A1 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
JP2003511075A (ja) * 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗ＨＢｓモノクローナル抗体
CN101606066A (zh) * 2006-10-30 2009-12-16 株式会社先端生命科学研究所 乙型肝炎病毒表面抗原的分析方法
CN101748129A (zh) * 2008-12-04 2010-06-23 上海裕隆临床检验中心有限公司 人源乙肝病毒表面抗体的制备方法
CN103483421B (zh) * 2012-06-11 2019-10-22 厦门大学 用于治疗hbv感染及相关疾病的多肽及抗体

Also Published As

Publication number Publication date
US10246494B2 (en) 2019-04-02
BR122020023349B1 (pt) 2023-02-07
KR102106782B1 (ko) 2020-05-07
BR112014030797A2 (pt) 2017-07-25
EP2860188A4 (en) 2016-04-27
US20150246948A1 (en) 2015-09-03
WO2013185558A1 (zh) 2013-12-19
JP6440259B2 (ja) 2018-12-19
CA2876020C (en) 2018-08-21
KR101944263B1 (ko) 2019-02-01
CA2876020A1 (en) 2013-12-19
KR20190011247A (ko) 2019-02-01
EP2860188A1 (en) 2015-04-15
ES2843675T3 (es) 2021-07-20
EP3308798A2 (en) 2018-04-18
AU2013276015B2 (en) 2017-04-20
KR20150043289A (ko) 2015-04-22
ES2834072T3 (es) 2021-06-16
IN2014DN10288A (pt) 2015-08-07
JP2015522563A (ja) 2015-08-06
EP3308798A3 (en) 2018-05-30
CN106046155B (zh) 2019-11-22
EP2860188B1 (en) 2020-10-21
CA2943258C (en) 2020-12-22
CA2943258A1 (en) 2013-12-19
US9751914B2 (en) 2017-09-05
CN103483421A (zh) 2014-01-01
CN103483421B (zh) 2019-10-22
EP3308798B1 (en) 2020-09-09
AU2013276015A1 (en) 2014-12-18
CN106046155A (zh) 2016-10-26
US20180002382A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
HK1203978A1 (en) Polypeptides and antibodies for treating hbv infection and related diseases hbv
HK1216538A1 (zh) 人類微管相關蛋白抗體
HK1207636A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1210463A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
DK3292875T3 (en) Compositions and methods for treating diseases
EP2943189A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEMYELINATING DISEASES
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
SG11201405559TA (en) Component and method for treating viral disease
ZA201408474B (en) Novel proteins for the treatment of cellulosic material
HK1213584A1 (zh) 用於治療癌症的 抗體及方法
SG11201402899TA (en) Methods and compositions for treating viral diseases
HK1199617A1 (en) Compositions and methods for treating viral diseases
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
ZA201302565B (en) Methods for treating hyperuricemia and related diseases